{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:47:11Z","timestamp":1788281231638,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016112","name":"Universit\u00e0 di Foggia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016112","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Pourpose<\/jats:title>\n                    <jats:p>To provide an update on the role of multiparametric magnetic resonance imaging (mpMRI) in active surveillance (AS) of prostate cancer, with particular focus on standardizing image acquisition and reporting through PI-RADS v2.1, PI-QUAL v2, and PRECISE v2, as well as their clinical implications in risk stratification and follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Narrative review of the literature and the most recent international guidelines on the use of mpMRI in patients undergoing AS. Selection criteria, follow-up protocols (12\u201324 months), imaging quality parameters (PI-QUAL v2), the longitudinal assessment system PRECISE v2, and the main radiological triggers for re-biopsy and multidisciplinary discussion were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline mpMRI improves candidate selection and reduces the risk of underestimating clinically significant disease. During follow-up, radiological progression shows a sensitivity of approximately 59% and specificity of approximately 75%, with a high negative predictive value (81\u201388%) but moderate positive predictive value. PRECISE v2 introduces updated categories, mandatory integration of image quality assessment, and systematic comparison with prior examinations, thereby improving reproducibility and comparability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The standardized integration of mpMRI, PI-QUAL v2, and PRECISE v2 enables more structured patient monitoring and supports multidisciplinary decision-making. However, mpMRI does not replace scheduled biopsies. The implementation of radiomics and artificial intelligence may further enhance the objectivity and effectiveness of active surveillance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00261-026-05738-0","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:22:45Z","timestamp":1786702965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The role of magnetic resonance imaging in the active surveillance of prostate cancer: state of the art"],"prefix":"10.1007","author":[{"given":"Valentina","family":"Testini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Eusebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Sortino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Pitoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Masino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Montatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-8330","authenticated-orcid":false,"given":"Giuseppe","family":"Guglielmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"5738_CR1","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1200\/JCO.2009.24.2180","volume":"28","author":"L Klotz","year":"2010","unstructured":"Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A, et al. Long-term outcomes of active surveillance for prostate cancer. J Clin Oncol. 2010;28:126\u2013131.","journal-title":"J Clin Oncol"},{"key":"5738_CR2","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1200\/JCO.2010.32.8112","volume":"29","author":"JJ Tosoian","year":"2011","unstructured":"Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol. 2011;29:2185\u20132190.","journal-title":"J Clin Oncol"},{"key":"5738_CR3","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.eururo.2012.05.072","volume":"62","author":"MA Dall\u2019Era","year":"2012","unstructured":"Dall\u2019Era MA, Albertsen PC, Bangma C, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012;62:976\u2013983.","journal-title":"Eur Urol"},{"key":"5738_CR4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.eururo.2014.10.050","volume":"67","author":"IG Schoots","year":"2015","unstructured":"Schoots IG, Padhani AR, Rouviere O, et al. Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. Eur Urol. 2015;67:627\u2013636.","journal-title":"Eur Urol"},{"key":"5738_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.21037\/tau.2017.12.24","volume":"7","author":"N Kinsella","year":"2018","unstructured":"Kinsella N, Helleman J, Bruinsma S, et al. Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Transl Androl Urol. 2018;7:83\u201397.","journal-title":"Transl Androl Urol"},{"key":"5738_CR6","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2214\/AJR.17.18030","volume":"209","author":"AB Rosenkrantz","year":"2017","unstructured":"Rosenkrantz AB, Taneja SS, Lepor H, et al. Prostate MRI and active surveillance: clinical utility and limitations. AJR Am J Roentgenol. 2017;209:1219\u20131228.","journal-title":"AJR Am J Roentgenol"},{"key":"5738_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/JU.0000000000001519","volume":"205","author":"T Stonier","year":"2021","unstructured":"Stonier T, Tin AL, Sjoberg DD, et al. Selecting patients with favorable risk grade group 2 prostate cancer for active surveillance\u2014does MRI have a role? J Urol. 2021;205:687\u2013694.","journal-title":"J Urol"},{"key":"5738_CR8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate imaging reporting and data system version 2.1: 2019 update. Eur Urol. 2019;76:340\u2013351.","journal-title":"Eur Urol"},{"key":"5738_CR9","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s00330-011-2377-y","volume":"22","author":"JO Barentsz","year":"2012","unstructured":"Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012;22:746\u2013757.","journal-title":"Eur Radiol"},{"key":"5738_CR10","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"CM Moore","year":"2018","unstructured":"Moore CM, Robertson NL, Arsanious N, et al. MRI-targeted biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378:1767\u20131777.","journal-title":"N Engl J Med"},{"key":"5738_CR11","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS). Lancet. 2017;389:815\u2013822.","journal-title":"Lancet"},{"key":"5738_CR12","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","volume":"75","author":"M van der Leest","year":"2019","unstructured":"van der Leest M, Cornel E, Isra\u00ebl B, et al. Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric MRI with subsequent MRI-targeted biopsy. Eur Urol. 2019;75:570\u2013578.","journal-title":"Eur Urol"},{"key":"5738_CR13","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378:1767\u20131777.","journal-title":"N Engl J Med"},{"issue":"11","key":"5738_CR14","doi-asserted-by":"publisher","first-page":"7068","DOI":"10.1007\/s00330-024-10795-4","volume":"34","author":"M de Rooij","year":"2024","unstructured":"de Rooij M, Allen C, Twilt JJ, et al. PI-QUAL version 2: update of the prostate MRI quality scoring system. Eur Radiol. 2024;34(11):7068\u20137079.","journal-title":"Eur Radiol"},{"key":"5738_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2214\/AJR.23.29518","volume":"221","author":"N Sanmugalingam","year":"2023","unstructured":"Sanmugalingam N, Westphalen AC, Turkbey B, et al. The PRECISE recommendations for prostate MRI in patients on active surveillance for prostate cancer: a critical review. AJR Am J Roentgenol. 2023;221:1\u201312.","journal-title":"AJR Am J Roentgenol"},{"key":"5738_CR16","first-page":"537","volume":"285","author":"F Giganti","year":"2017","unstructured":"Giganti F, Moore CM, Kasivisvanathan V, et al. PRECISE: a reporting system for MRI in active surveillance of prostate cancer. Radiology. 2017;285:537\u2013546.","journal-title":"Radiology"},{"key":"5738_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0302-2838(24)01391-5","volume":"85","author":"C Englman","year":"2024","unstructured":"Englman C, Adebusoye B, Maffei D, et al. PRECISE version 2: updated recommendations for reporting prostate MRI in patients on active surveillance for prostate cancer. Eur Urol. 2024;85:234\u2013245.","journal-title":"Eur Urol"},{"key":"5738_CR18","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1148\/radiol.2015151089","volume":"279","author":"P Recabal","year":"2016","unstructured":"Recabal P, Assel M, Sjoberg DD, et al. Prostate MRI in active surveillance: role of apparent diffusion coefficient. Radiology. 2016;279:805\u2013814.","journal-title":"Radiology"},{"key":"5738_CR19","first-page":"2169","volume":"19","author":"AR Padhani","year":"2009","unstructured":"Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted MRI in prostate cancer: ADC as a biomarker. Eur Radiol. 2009;19:2169\u20132177.","journal-title":"Eur Radiol"},{"key":"5738_CR20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1148\/radiol.11091409","volume":"259","author":"T Hambrock","year":"2011","unstructured":"Hambrock T, Somford DM, Huisman HJ, et al. Relationship between apparent diffusion coefficients and Gleason grade. Radiology. 2011;259:453\u2013461.","journal-title":"Radiology"},{"key":"5738_CR21","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1007\/s00330-019-06557-2","volume":"30","author":"F Giganti","year":"2020","unstructured":"Giganti F, Allen C, Emberton M, et al. Prostate Imaging Quality (PI-QUAL): a new quality control scoring system for prostate MRI. Eur Radiol. 2020;30:2729\u20132738.","journal-title":"Eur Radiol"},{"key":"5738_CR22","first-page":"144","volume":"269","author":"F Bratan","year":"2013","unstructured":"Bratan F, Niaf E, Melodelima C, et al. Influence of imaging quality on prostate MRI interpretation. Radiology. 2013;269:144\u2013153.","journal-title":"Radiology"},{"issue":"3","key":"5738_CR23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2214\/AJR.17.17790","volume":"209","author":"VA Morgan","year":"2017","unstructured":"Morgan VA, Riches SF, Thomas K, et al. Monitoring Tumor Volume in Patients With Prostate Cancer Undergoing Active Surveillance: Is MRI Apparent Diffusion Coefficient Indicative of Tumor Growth? American Journal of Roentgenology. 2017;209(3):533\u2013539.","journal-title":"American Journal of Roentgenology"},{"key":"5738_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2022","unstructured":"Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Eur Urol. 2022;79:243\u2013262.","journal-title":"Eur Urol"},{"key":"5738_CR25","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2024. Available from: https:\/\/www.nccn.org"},{"issue":"4","key":"5738_CR26","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.eururo.2014.10.05","volume":"67","author":"IG Schoots","year":"2015","unstructured":"Schoots IG, Petrides N, Giganti F, et al. Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. Eur Urol. 2015;67(4):627-636. https:\/\/doi.org\/10.1016\/j.eururo.2014.10.05","journal-title":"Eur Urol"},{"key":"5738_CR27","unstructured":"European Association of Urology. EAU Guidelines on Prostate Cancer. 2025 Edition."},{"issue":"5","key":"5738_CR28","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.eururo.2021.05.001","volume":"80","author":"P Rajwa","year":"2021","unstructured":"Rajwa P, Pradere B, Quhal F, et al. Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis. European Urology. 2021;80(5):549\u2013563. https:\/\/doi.org\/10.1016\/j.eururo.2021.05.001.","journal-title":"European Urology"},{"issue":"2","key":"5738_CR29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.eururo.2016.08.023","volume":"72","author":"GN Tran","year":"2017","unstructured":"Tran GN, Leapman MS, Nguyen HG, et al. Magnetic resonance imaging-ultrasound fusion biopsy during prostate cancer active surveillance. Eur Urol. 2017;72(2):275\u2013281.","journal-title":"Eur Urol"},{"key":"5738_CR30","first-page":"217","volume":"6","author":"S Gaur","year":"2020","unstructured":"Gaur S, Harmon SA, Turkbey B, et al. Radiomics and artificial intelligence in prostate MRI. Eur Urol Focus. 2020;6:217\u2013225.","journal-title":"Eur Urol Focus"},{"key":"5738_CR31","first-page":"1","volume":"33","author":"J Bleker","year":"2023","unstructured":"Bleker J, Kwee TC, Dierckx RAJO, et al. Artificial intelligence for prostate cancer progression during active surveillance. Eur Radiol. 2023;33:1\u201310.","journal-title":"Eur Radiol"},{"issue":"12","key":"5738_CR32","doi-asserted-by":"publisher","first-page":"7698","DOI":"10.1007\/s00330-024-10869-3","volume":"34","author":"V Bozgo","year":"2024","unstructured":"Bozgo V, Roest C, van Oort I, Yakar D, Huisman H, de Rooij M. Prostate MRI and artificial intelligence during active surveillance: should we jump on the bandwagon?. Eur Radiol. 2024;34(12):7698\u20137704.\u00a0https:\/\/doi.org\/10.1007\/s00330-024-10869-3","journal-title":"Eur Radiol"},{"key":"5738_CR33","doi-asserted-by":"publisher","unstructured":"Cutaia G, La Tona G, Comelli A, et al. Radiomics and Prostate MRI: Current Role and Future Applications. J Imaging. 2021;7(2):34. Published 2021 Feb 11.1 https:\/\/doi.org\/10.3390\/jimaging7020034","DOI":"10.3390\/jimaging7020034"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-026-05738-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-026-05738-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-026-05738-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:22:49Z","timestamp":1786702969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-026-05738-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":33,"alternative-id":["5738"],"URL":"https:\/\/doi.org\/10.1007\/s00261-026-05738-0","relation":{},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}